According to the latest market report published by Credence Research, Inc. Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 12.4 Bn in 2016, and is expected to reach US$ 17.4 Bn by 2025, expanding at a CAGR of 3.9% from 2017 to 2025.

Browse the full report Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 2025 at http://www.credenceresearch.com/report/chronic-kidney-disease-ckd-drugs-market

Market Insights

Chronic Kidney Disease (CKD) is also known as chronic kidney failure characterized by gradual loss of kidney function. There are different types of medications available in market. Medicines cannot reverse CKD, however they are used to treat complications and to slow further kidney damage. Factors such as rising incidence of cardiovascular disorders and diabetes, increasing geriatric population, significant unmet needs, promising pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) and increasing prevalence of CKD would further drive the growth of CKD drugs market globally. However, preferable use of generic drugs and in some countries may negatively impacting the market growth. For the purpose of study, global chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as antihypertensive, antihyperlipidemic, anemia treatment medications, swelling and other treatment medications. It is observed that, in the base year 2016, antihypertensive held largest market share because high blood pressure is major complication associated with CKD. Currently, CKD drugs market is dominated by North America, due to factors such as higher cost of medication, changing healthcare reimbursement environment and upsurge in funding by government agencies and private organizations in healthcare system driving the growth of CKD drugs market in North America. It is estimated that Asia Pacific will grow at fastest CAGR during forecast period due to the factors such as increasing incidence of diabetes and hypertension, continues development in economic conditions, increase in health care spending, populous countries and developing healthcare infrastructure would drive market growth in Asia Pacific during forecast period.

Market Competition Assessment:

The Chronic Kidney Disease (CKD) Drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbVie, Inc., Allergan plc. Amgen Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, FibroGen, GlaxoSmithKline plc., Johnson & Johnson, Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co. Ltd., Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and other. 

Key Market Movements:

• Factors such as rising incidence of CKD, increasing geriatric population, favorable reimbursement policies in some countries and high degree of R&D activity in development of CKD drugs are driving the market growth globally.
• Due to the high unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment, this would further influence the market growth of CKD drugs globally.
• However, poor patient compliance in some countries and preferable use of generic drugs would negatively impact market growth of CKD Drugs. 

Browse the full report Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 2025 at http://www.credenceresearch.com/report/chronic-kidney-disease-ckd-drugs-market

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months or years. Early on there are typically no symptoms. Later, leg swelling, feeling tired, vomiting, loss of appetite, or confusion may develop.  Complications may include heart disease, high blood pressure, bone disease, or anemia.

Causes of chronic kidney disease include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease.  Risk factors include a family history of the condition. Diagnosis is generally by blood tests to measure the glomerular filtration rate and urine tests to measure albumin.Further tests such as an ultrasound or kidney biopsy may be done to determine the underlying cause. A number of different classification systems exist.

Screening at-risk people is recommended.  Initial treatments may include medications to manage blood pressure, blood sugar, and lower cholesterol. NSAIDs should be avoided. Other recommended measures include staying active and certain dietary changes. Severe disease may require hemodialysis, peritoneal dialysis, or a kidney transplant. Treatments for anemia and bone disease may also be required.

Source: Wikipedia

 Latest Reports:

Pulmonary Drug Delivery Devices Market: http://www.credenceresearch.com/press/global-pulmonary-drug-delivery-devices-market

Blog: https://globenewswire.com/news-release/2018/03/19/1441970/0/en/Candles-Market-is-Expected-to-Reach-US-11-707-76-Million-By-2025-Credence-Research.html

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com